Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 03/28/24
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024PRNewsWire • 03/26/24
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual MeetingPRNewsWire • 01/30/24
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/14/23
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business HighlightsPRNewsWire • 11/14/23
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submissionPRNewsWire • 11/06/23
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETINGPRNewsWire • 11/02/23
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina SocietyPRNewsWire • 10/11/23
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare ConferencePRNewsWire • 09/08/23
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusionPRNewsWire • 09/07/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KODPRNewsWire • 08/19/23
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business HighlightsPRNewsWire • 08/14/23
Kodiak Sciences discontinues development of eye disorder therapeutic; shares plummetProactive Investors • 07/24/23
Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatmentMarket Watch • 07/24/23